Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

BACKGROUND: HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-derived suppressor cells. Studies have demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilusic, Marijo, Heery, Christopher R., Collins, Julie M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Marté, Jennifer L., Strauss, Julius, Gatti-Mays, Margaret E., Schlom, Jeffrey, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729083/
https://www.ncbi.nlm.nih.gov/pubmed/31488216
http://dx.doi.org/10.1186/s40425-019-0706-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729083/
https://www.ncbi.nlm.nih.gov/pubmed/31488216
http://dx.doi.org/10.1186/s40425-019-0706-x

Ejemplares similares